CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials with SYH-2061 injection for the treatment of IgA nephropathy and other complement-mediated diseases.
Hamlet Biopharma AB has announced the presentation of new preclinical-stage molecules that have originated from its long-term collaboration with Lund University and Linnane Pharma AB with the aim of treating bacterial infections by targeting the disease response of the host rather than the pathogen itself.
Convalife Pharmaceuticals Co. Ltd. has presented data for their bispecific antibody CVL-006, which targets both PD-1 and VEGF-A. CVL-006 blocks both the PD-1-driven immune pathway plus VEGF-A-driven angiogenesis, thus conferring a dual mechanism for superior antitumoral activity.
Biogen Inc. and Vanqua Bio Inc. have announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical oral C5aR1 antagonist with the potential to address a broad range of inflammatory disorders.
SVF Vaccines AB, a portfolio company of Karolinska Development AB, has presented positive results from a preclinical study of its immunotherapy SVF-001 targeting chronic hepatitis B (HBV) and D viruses (HDV).
Neumora Therapeutics Inc. has reported preclinical data for NMRA-215, a brain-penetrant, oral NLRP3 inhibitor in development for obesity, suggesting potential utility as a monotherapy as well as in combination with a GLP-1 agonist.
Cancer of the uterus is the most common gynecological malignancy in the U.S., with over 60,000 diagnoses per year, where incidence and mortality have increased through the years. About 30%-40% of patients with high-grade disease harbor mutations in the PPP2R1A gene, which encodes the primary subunit of protein phosphatase 2A, with hotspots being P179R and S256F.
At this year’s AACR-NCI-EORTC conference, several presentations brought to light new ways to tackle the treatment of genomically unstable cancers. Genomically unstable cancers can be treated by exploiting their repair dependencies, inducing catastrophic DNA damage, or harnessing immune responses to instability.
RSS
